Please login to the form below

Not currently logged in
Email:
Password:

Silence Therapeutics

This page shows the latest Silence Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Optimum wins Silence Therapeutics account

Optimum wins Silence Therapeutics account

Optimum wins Silence Therapeutics account. The healthcare communications group will advise in financial PR. ... London, UK-based Optimum Strategic Communications has been appointed by RNAi-focused Silence Therapeutics.

Latest news

  • mRNA - message received mRNA - message received

    mRNA replacement opens up entirely new therapeutic areas,” according to Ali Mortazavi, chief executive of UK firm Silence Therapeutics that has just raised almost £40m ($62m) in a fundraising round. “ ... Silence Therapeutics. undisclosed. Antigen

  • Sanofi strikes $700m rare diseases deal Sanofi strikes $700m rare diseases deal

    This pipeline features a series of RNAi therapeutics designed to 'silence' mutated genes in rare genetic diseases in order to stop the disease-causing proteins from being formed.

  • Thomas Christély steps down as Silence Therapeutics CEO after five months

    Thomas Christély has resigned from his role as CEO at Silence Therapeutics after only five months. ... Christély was only appointed CEO in September 2011, having previously held the role of CEO at Silence Therapeutics AG - a subsidiary of Silence

  • Oncology bias in pharma deals

    Silence Therapeutics and miRNA Therapeutics have also signed a collaboration to evaluate delivery of novel microRNA Therapeutics, via Silence's AtuPLEX and DBTC delivery systems. ... not known. Silence Therapeutics/ miRNA Therapeutics. R&D collaboration.

  • Dr Georg Buchner joins Silence Therapeutics

    Dr Georg Buchner joins Silence Therapeutics. He assumes a business development role at the London-based biotech. ... London-based biotech Silence Therapeutics has appointed Dr Georg Buchner VP, business development.

More from news
Approximately 1 fully matching, plus 11 partially matching documents found.

Latest appointments

  • Industry round up: appointments Industry round up: appointments

    Industry round up: appointments. Destiny Pharma, Silence Therapeutics and Concept Life Sciences add to its teams. ... At Silence Therapeutics, Jenkins will be heading the clinical development function, reporting directly to executive chair Annalisa

  • Silence Therapeutics appoints Dr Annalisa Jenkins as non-executive chair Silence Therapeutics appoints Dr Annalisa Jenkins as non-executive chair

    Silence Therapeutics appoints Dr Annalisa Jenkins as non-executive chair. The Dimension Therapeutics CEO succeeds Dr Stephen Parker, who becomes a non-executive director. ... RNA-focused group Silence Therapeutics has appointed Dimension Therapeutics

  • Silence Therapeutics' Ali Mortazavi appointed chairman of ultromics Silence Therapeutics' Ali Mortazavi appointed chairman of ultromics

    Silence Therapeutics' Ali Mortazavi appointed chairman of ultromics. Takes up the non-executive role at the AI-focused medical imaging firm. ... Silence Therapeutics' chief executive officer Ali Mortazavi has been appointed non-executive chairman of

  • Silence Therapeutics adds to leadership team Silence Therapeutics adds to leadership team

    Silence Therapeutics adds to leadership team. Dr Dmitry Samarsky and Dr Andy Richards join. ... London-headquartered RNA therapeutics specialist Silence Therapeutics has appointed Dr Dmitry Samarsky as its new chief scientific officer, to take effect on

  • Stuart Collinson joins Silence Therapeutics Stuart Collinson joins Silence Therapeutics

    Stuart Collinson joins Silence Therapeutics. He replaces Simon Sturge as non-executive director. ... Silence Therapeutics has appointed Dr Stuart Collinson as its new non-executive director and chair of its remuneration committee with immediate effect.

More from appointments
Approximately 7 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics